Last reviewed · How we verify
GSK4382276A Dose level 3
At a glance
| Generic name | GSK4382276A Dose level 3 |
|---|---|
| Also known as | Flu mRNA |
| Sponsor | GlaxoSmithKline |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study on the Safety, Reactogenicity and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older Adults (PHASE1)
- A Study to Assess the Safety and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older Adults (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GSK4382276A Dose level 3 CI brief — competitive landscape report
- GSK4382276A Dose level 3 updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI